Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
ZolgensmaⓇ grew 18% cc with increasing access ex-US
Sales evolution
USD m, % cc
Ex-US
US
319
+18% cc
1 GROWTH
C Ezolgensma K
KL
Q1 highlights
Ex-US sales grew +32% cc, while US sales steady
☐
363
"
250
200
119
113
Q1 2021
Q1 2022
1. With investigational OAV101 intrathecal administration
10 Investor Relations | Q1 2022 Results
Over 2000 patients have been treated worldwide
Future growth drivers
◉
Increase in newborn screening: currently at 95% in US, 25% in EU
OAV101 IT data¹: STEER currently enrolling; STRENGTH to start in 2H22
New data at MDA 2022 reinforce Zolgensma IV clinical benefit
Age-appropriate motor milestones in pre-symptomatic children with 3-copy SMN-2
backup gene (SPR1NT)
Post-hoc analysis (START and STR1VE) of children with Type 1 SMA achieved /
maintained important measures of bulbar function
NOVARTIS | Reimagining MedicineView entire presentation